Gene · 970
NIH grants2,135
NIH grants whose papers are about the gene, through NIH's grant-paper links.
721 to 740 of 2,135
Download this page as JSON| Grant | Title | CD70 papers | Newest fiscal year |
|---|---|---|---|
| T32AI052066 | Molecular Pathogenesis of Infectious Diseases | 1 | 2022 |
| T32AI106677 | Basic Training at the Intersection of Innate and Adaptive Immunity in Disease | 1 | 2022 |
| T32GM067547 | BMI Bioinformatics Training Grant | 1 | 2022 |
| T32GM080189 | The Chemistry-Biology Interface Program at Johns Hopkins University | 1 | 2022 |
| T32HL007609 | Training Program in Hypertension | 1 | 2022 |
| U01AI142817 | Expanding CRISPR-Cas editing technology through exploration of novel Cas proteins and DNA repair systems | 1 | 2022 |
| U01AI157189 | A novel human T-cell platform to define biological effects of genome editing | 1 | 2022 |
| U01CA224276 | Phenotype Interactions in SCLC Development and Detection | 1 | 2022 |
| U01CA233100 | Molecular and immune drivers of immunotherapy responsiveness in prostate cancer | 1 | 2022 |
| U01DE028227 | Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers | 1 | 2022 |
| U24OD023176 | Technology to Empower Changes in Health (TECH) Network Participant Technologies Center | 1 | 2022 |
| U24OD026641 | Development of Swine Reporter Models for Testing Somatic Cell Genome Editing Tools | 1 | 2022 |
| U2COD023196 | Data and Research Support Center | 1 | 2022 |
| U54CA217450 | Phenotype Heterogeneity and Dynamics in SCLC | 1 | 2022 |
| U54CA225088 | Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs | 1 | 2022 |
| U54CA244438 | UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer | 1 | 2022 |
| UL1TR002240 | Michigan Institute for Clinical and Health Research (MICHR) | 1 | 2022 |
| UL1TR002494 | University of Minnesota Clinical and TranslationalmScience Institute (UMN CTSI) | 1 | 2022 |
| UL1TR002541 | The Harvard Clinical and Translational Science Center | 1 | 2022 |
| UM1CA154967 | Cancer Immunotherapy Trials Network Central Operations and Statistical Center | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/grants?page=37